

Peter Andreas Fasching

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9520251/publications.pdf>

Version: 2024-02-01

422
papers

41,100
citations

5268

83
h-index

3182

186
g-index

465
all docs

465
docs citations

465
times ranked

34591
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014, 384, 164-172.	13.7	3,224
2	Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. <i>Journal of Clinical Oncology</i> , 2012, 30, 1796-1804.	1.6	2,062
3	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 617-628.	27.0	1,610
4	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	27.0	1,542
5	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology, The</i> , 2018, 19, 40-50.	10.7	1,327
6	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
7	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960
8	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 747-756.	10.7	810
9	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology, The</i> , 2012, 13, 385-394.	10.7	753
10	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
11	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472.	1.6	704
12	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	6.3	596
13	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532
14	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-311.	1.6	521
15	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	21.4	513
16	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
17	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	493
18	Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2024-2031.	1.6	487

#	ARTICLE	IF	CITATIONS
19	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524.	27.0	482
20	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 299-309.	27.0	473
21	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1429.	7.4	468
22	Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. <i>Journal of Clinical Oncology</i> , 2011, 29, 3351-3357.	1.6	456
23	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 556-567.	27.0	444
24	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
25	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841.	21.4	426
26	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 135-144.	10.7	425
27	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
28	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	21.4	357
29	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
30	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
31	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
32	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	21.4	309
33	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1378.	7.1	300
34	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
35	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	21.4	279
36	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	21.4	276

#	ARTICLE	IF	CITATIONS
37	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
38	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <i>BMC Cancer</i> , 2011, 11, 486.	2.6	260
39	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
40	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	21.4	256
41	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	10.7	248
42	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	21.4	235
43	PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3212-3220.	1.6	231
44	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230
45	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 145-156.	2.5	228
46	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. <i>Journal of the National Cancer Institute</i> , 2018, 110, 855-862.	6.3	225
47	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
48	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217
49	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	6.2	201
50	Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2015-2023.	1.6	194
51	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	21.4	184
52	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	12.8	178
53	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	174
54	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. <i>Human Molecular Genetics</i> , 2012, 21, 5373-5384.	2.9	168

#	ARTICLE	IF	CITATIONS
55	<i>CHK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	1.6	162
56	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
57	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	2.9	152
58	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CHK2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	1.6	152
59	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	1.6	152
60	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	2.8	145
61	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
62	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141
63	Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. <i>PLoS Genetics</i> , 2013, 9, e1003284.	3.5	136
64	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
65	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
66	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
67	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6240-6249.	0.9	109
68	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. <i>Nature Communications</i> , 2014, 5, 5303.	12.8	109
69	Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients. <i>Onkologie</i> , 2011, 34, 362-367.	0.8	106
70	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
71	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	7.0	102
72	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1156-1166.	2.5	101

#	ARTICLE	IF	CITATIONS
73	Risk of Estrogen Receptor-Positive and -Negative Breast Cancer and Single-Nucleotide Polymorphism 2q35-rs13387042. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1012-1018.	6.3	99
74	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	6.3	99
75	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. <i>International Journal of Cancer</i> , 2017, 140, 95-102.	5.1	99
76	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	6.2	98
77	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
78	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	5.0	97
79	The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R58.	5.0	95
80	Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2469-2477.	3.7	95
81	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. <i>Journal of Clinical Oncology</i> , 2019, 37, 2226-2234.	1.6	95
82	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309.	3.2	94
83	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. <i>Breast Cancer Research</i> , 2015, 17, 129.	5.0	93
84	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
85	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
86	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
87	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2281-2287.	1.6	86
88	Association of ESR1 gene tagging SNPs with breast cancer risk. <i>Human Molecular Genetics</i> , 2009, 18, 1131-1139.	2.9	84
89	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBC 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	2.8	84
90	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. <i>Breast Cancer Research</i> , 2010, 12, R110.	5.0	82

#	ARTICLE	IF	CITATIONS
91	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 671-676.	2.5	82
92	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	2.9	80
93	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
94	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98.	2.5	77
95	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	21.4	77
96	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020, 80, 5427-5434.	0.9	77
97	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009, 18, 135-141.	2.2	76
98	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76
99	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.0	76
100	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab “ Results of the randomised GeparQuinto study (GBC 44). <i>European Journal of Cancer</i> , 2013, 49, 2284-2293.	2.8	75
101	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	1.4	72
102	Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. <i>European Journal of Radiology</i> , 2006, 60, 398-404.	2.6	71
103	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
104	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
105	Role of genetic polymorphisms and ovarian cancer susceptibility. <i>Molecular Oncology</i> , 2009, 3, 171-181.	4.6	69
106	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
107	Lymphedema in breast cancer survivors: Assessment and information provision in a specialized breast unit. <i>Patient Education and Counseling</i> , 2007, 66, 311-318.	2.2	65
108	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012, 14, R59.	5.0	65

#	ARTICLE	IF	CITATIONS
109	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	2.5	64
110	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 77-91.	3.1	62
111	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	2.8	62
112	The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms. <i>Journal of Affective Disorders</i> , 2012, 136, 1192-1197.	4.1	60
113	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	6.2	59
114	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	2.6	59
115	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 927-948.	1.8	59
116	Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1610-1616.	2.5	57
117	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56
118	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	2.5	56
119	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
120	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14.	1.4	55
121	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015, 75, 2457-2467.	0.9	55
122	Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy. <i>Alcohol</i> , 2016, 54, 39-44.	1.7	55
123	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074.	5.1	54
124	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
125	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
126	Mammographic density as a risk factor for breast cancer in a German case-control study. <i>European Journal of Cancer Prevention</i> , 2011, 20, 1-8.	1.3	53

#	ARTICLE	IF	CITATIONS
127	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014, 23, 6096-6111.	2.9	53
128	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52
129	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	5.1	51
130	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	1.4	51
131	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	2.5	51
132	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
133	Breast Volumetry Using a Three-Dimensional Surface Assessment Technique. <i>Aesthetic Plastic Surgery</i> , 2011, 35, 847-855.	0.9	50
134	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	2.9	50
135	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	2.5	49
136	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.9	49
137	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor-“Negative Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2010, 102, 650-662.	6.3	48
138	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322.	4.3	48
139	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309.	1.4	47
140	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	2.5	45
141	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. <i>International Journal of Cancer</i> , 2012, 131, 2643-2649.	5.1	44
142	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
143	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-“positive (HR+), human epidermal growth factor receptor 2-“negative (HER2-“) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS597-TPS597.	1.6	44
144	Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. <i>Journal of Psychiatric Research</i> , 2012, 46, 1109-1117.	3.1	43

#	ARTICLE	IF	CITATIONS
145	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	5.0	43
146	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43
147	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
148	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1239-1245.	1.7	42
149	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 744.	7.1	42
150	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2675-2683.	7.0	41
151	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170.	2.8	41
152	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	2.9	40
153	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
154	Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. <i>Biochemical Pharmacology</i> , 2012, 83, 480-488.	4.4	39
155	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39
156	Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 755-763.	1.7	39
157	Patient survival and tumor characteristics associated with CHEK2:p.1157T – findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016, 18, 98.	5.0	39
158	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
159	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer – Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	1.6	39
160	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
161	Invasive Breast Cancer: Recognition of Molecular Subtypes. <i>Breast Care</i> , 2011, 6, 258-264.	1.4	38
162	Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	38

#	ARTICLE	IF	CITATIONS
163	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
164	Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492.	1.8	38
165	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. <i>JMIR Cancer</i> , 2017, 3, e11.	2.4	38
166	Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 873-882.	2.5	37
167	Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. <i>International Journal of Cancer</i> , 2008, 123, 2871-2879.	5.1	37
168	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	6.2	37
169	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 885-892.	2.5	36
170	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012, 33, 1123-1132.	2.5	35
171	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	2.5	35
172	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	5.1	35
173	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015, 136, E685-96.	5.1	34
174	Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. <i>Human Genetics</i> , 2015, 134, 231-245.	3.8	34
175	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	2.2	34
176	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33
177	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	4.9	33
178	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	2.5	32
179	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	1.4	32
180	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 59-71.	2.5	32

#	ARTICLE	IF	CITATIONS
181	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3986-3995.	7.0	32
182	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
183	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1638-1648.	2.5	31
184	HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 193-203.	2.5	31
185	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	5.1	31
186	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885.	5.1	31
187	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	2.6	30
188	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
189	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 429-440.	2.5	29
190	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2~ Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4242-4249.	7.0	29
191	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
192	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10004.	4.3	29
193	Delivery mode and the course of pre- and postpartum depression. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1407-1412.	1.7	28
194	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	1.3	28
195	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93.	1.3	28
196	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
197	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 633-644.	1.8	28
198	Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 889-895.	1.7	28

#	ARTICLE	IF	CITATIONS
199	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	1.8	28
200	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2222-2231.	2.5	27
201	Meconium Indicators of Maternal Alcohol Abuse during Pregnancy and Association with Patient Characteristics. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	27
202	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27
203	Effects of prenatal alcohol consumption on cognitive development and ADHD-related behaviour in primary school age: a multilevel study based on meconium ethyl glucuronide. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2018, 59, 110-118.	5.2	27
204	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2584-2591.	7.0	27
205	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26
206	ADSCs and adipocytes are the main producers in the autotaxin–lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. <i>BMC Cancer</i> , 2018, 18, 1273.	2.6	26
207	Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	1.8	26
208	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020, 130, 92-101.	2.8	26
209	Assessment of breast cancer tumour size using six different methods. <i>European Radiology</i> , 2011, 21, 1180-1187.	4.5	25
210	Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case–control study. <i>BMC Cancer</i> , 2015, 15, 751.	2.6	25
211	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 851-861.	3.1	25
212	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020, 54, 148-154.	2.2	25
213	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts. <i>Breast Care</i> , 2020, 15, 82-95.	1.4	25
214	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
215	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134.	5.2	25
216	Pain perception and detailed visual pain mapping in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 105-110.	2.5	24

#	ARTICLE	IF	CITATIONS
217	Two naturally occurring variants of the serotonin receptor gene <i>HTR3C</i> are associated with nausea in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 7-14.	2.8	24
218	Overexpression of <i>SERBP1</i> (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. <i>BMC Cancer</i> , 2012, 12, 597.	2.6	24
219	<i>CYP2B6</i> is associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2014, 134, 426-430.	5.1	24
220	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24
221	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	2.5	24
222	Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017, 145, 142-147.	1.4	24
223	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
224	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144.	5.0	24
225	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021, 154, 128-137.	2.8	24
226	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908.	2.5	23
227	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
228	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
229	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	2.5	22
230	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
231	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 165-175.	2.0	22
232	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
233	Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 405-412.	1.3	21
234	Genetic Variants in the Genes of the Stress Hormone Signalling Pathway and Depressive Symptoms during and after Pregnancy. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	21

#	ARTICLE	IF	CITATIONS
235	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678.	1.8	21
236	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018, 18, 175-183.	2.4	21
237	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	3.5	21
238	Update Breast Cancer 2019 Part 2 " Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	1.8	21
239	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 142.	5.0	21
240	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
241	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	1.8	20
242	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017, 141, 1830-1840.	5.1	20
243	Update Breast Cancer 2018 (Part 1) " Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
244	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	1.4	20
245	Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	1.6	20
246	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 66.	2.6	19
247	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. <i>Breast Cancer Research</i> , 2015, 17, 110.	5.0	19
248	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. <i>BMC Cancer</i> , 2015, 15, 587.	2.6	19
249	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
250	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016, 139, 1967-1974.	5.1	19
251	Children of Prenatally Depressed Mothers: Externalizing and Internalizing Symptoms are Accompanied by Reductions in Specific Social-Emotional Competencies. <i>Journal of Child and Family Studies</i> , 2017, 26, 3135-3144.	1.3	19
252	Update Breast Cancer 2017 " Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19

#	ARTICLE	IF	CITATIONS
253	Prenatal Alcohol Exposure Is Associated With Adverse Cognitive Effects and Distinct Whole-Genome DNA Methylation Patterns in Primary School Children. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 125.	2.0	19
254	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	12.8	19
255	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 623-642.	2.5	19
256	Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study. <i>JMIR Formative Research</i> , 2022, 6, e33635.	1.4	19
257	Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 395-400.	1.7	18
258	Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	18
259	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
260	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017, 8, 1632.	12.8	18
261	Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. <i>Early Human Development</i> , 2018, 119, 1-7.	1.8	18
262	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 206-211.	2.5	18
263	Update Breast Cancer 2019 Part 4 "Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	1.8	18
264	Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6-9-year old children. <i>Physiology and Behavior</i> , 2019, 209, 112584.	2.1	18
265	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , 2021, 140, 1353-1365.	3.8	18
266	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	2.8	18
267	Update Breast Cancer 2019 Part 1 "Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	1.8	17
268	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor I±. <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	7.0	17
269	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. <i>Journal of Clinical Oncology</i> , 2018, 36, 522-522.	1.6	17
270	Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. <i>Breast</i> , 2008, 17, 640-645.	2.2	16

#	ARTICLE	IF	CITATIONS
271	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014, 5, 4051.	12.8	16
272	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. <i>BMC Cancer</i> , 2018, 18, 926.	2.6	16
273	Update Breast Cancer 2019 Part 5 â€œ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	1.8	16
274	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. <i>Breast Cancer Research</i> , 2019, 21, 60.	5.0	16
275	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75.	2.0	16
276	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptorâ€“Positive Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2020, 26, 6523-6534.	7.0	16
277	Update Breast Cancer 2020 Part 1 â€œ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 277-287.	1.8	16
278	Endocrine Treatment for Breast Cancer Patients Revisitedâ€“History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021, 13, 5643.	3.7	16
279	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
280	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
281	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
282	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750.	3.3	15
283	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancerâ€“results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , 2020, 22, 111.	5.0	15
284	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15
285	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
286	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	5.0	14
287	Association of molecular subtypes with breast cancer risk factors. <i>European Journal of Cancer Prevention</i> , 2015, 24, 484-490.	1.3	14
288	The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016, 39, 290-300.	1.3	14

#	ARTICLE	IF	CITATIONS
289	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434.	2.5	14
290	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	1.8	14
291	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3117-3128.	1.1	14
292	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. <i>British Journal of Cancer</i> , 2022, 126, 1715-1724.	6.4	14
293	Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. <i>Pain</i> , 2011, 152, 1298-1303.	4.2	13
294	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 337-344.	1.7	13
295	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
296	Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1473-1481.	2.8	13
297	HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1123-1133.	1.8	13
298	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	2.2	13
299	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
300	Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. <i>European Journal of Cancer Prevention</i> , 2014, 23, 151-157.	1.3	12
301	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	2.9	12
302	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316.	2.5	12
303	Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. <i>Breast Care</i> , 2016, 11, 313-314.	1.4	12
304	Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). <i>Journal of Surgical Oncology</i> , 2017, 115, 238-242.	1.7	12
305	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 701-708.	2.5	12
306	Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?. <i>Lancet Oncology</i> , The, 2018, 19, 150-151.	10.7	12

#	ARTICLE	IF	CITATIONS
307	The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 747-758.	2.5	12
308	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	5.1	12
309	Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. <i>European Journal of Cancer Prevention</i> , 2019, 28, 515-521.	1.3	12
310	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020, 12, 2787.	3.7	12
311	Update Breast Cancer 2020 Part 3 " Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114.	1.8	12
312	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
313	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. <i>International Journal of Cancer</i> , 2020, 147, 2458-2468.	5.1	12
314	Update Breast Cancer 2020 Part 2 " Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398.	1.8	12
315	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2022, 160, 100-111.	2.8	12
316	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. <i>Cancers</i> , 2022, 14, 521.	3.7	12
317	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 135-141.	1.7	11
318	Translational Highlights in Breast and Ovarian Cancer 2019 " Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	1.8	11
319	Update Breast Cancer 2020 Part 4 " Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	1.8	11
320	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 279-285.	2.4	10
321	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
322	Updates on the role of receptor activator of nuclear factor κ B/receptor activator of nuclear factor κ B ligand/osteoprotegerin pathway in breast cancer risk and treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 4-11.	2.0	10
323	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018, 59, 1406-1413.	1.1	10
324	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	1.0	10

#	ARTICLE	IF	CITATIONS
325	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII and BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 557-568.	2.5	10
326	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 311-324.	2.5	10
327	The association between prenatal alcohol consumption and preschool child stress system disturbance. <i>Developmental Psychobiology</i> , 2021, 63, 687-697.	1.6	10
328	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. <i>Cancers</i> , 2021, 13, 2088.	3.7	10
329	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	1.8	10
330	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	3.0	9
331	Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2018, 17, 941-951.	2.0	9
332	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793.	3.2	9
333	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1896-1904.	7.0	9
334	Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 699-707.	1.8	9
335	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
336	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 421-429.	1.4	9
337	Correlates of mammographic density in B-mode ultrasound and real time elastography. <i>European Journal of Cancer Prevention</i> , 2012, 21, 343-349.	1.3	8
338	The UGT1A6_19_GG genotype is a breast cancer risk factor. <i>Frontiers in Genetics</i> , 2013, 4, 104.	2.3	8
339	Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	1.8	8
340	Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. <i>Breast</i> , 2019, 44, 81-89.	2.2	8
341	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020, 20, 86.	2.7	8
342	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8

#	ARTICLE	IF	CITATIONS
343	Breast cancer patients'™ satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 147-156.	1.7	7
344	Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. <i>Brain Sciences</i> , 2021, 11, 154.	2.3	7
345	Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry™ Comparison of Three Different GPA Prognostic Scores. <i>Cancers</i> , 2021, 13, 844.	3.7	7
346	Association of genomic variants at <sc><i>PAX8</i></sc> and <sc><i>PBX2</i></sc> with cervical cancer risk. <i>International Journal of Cancer</i> , 2021, 149, 893-900.	5.1	7
347	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
348	A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GePAROLA.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS1096-TPS1096.	1.6	7
349	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017, 8, 64670-64684.	1.8	7
350	Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis. <i>Gynecological Endocrinology</i> , 2009, 25, 726-733.	1.7	6
351	Visual pain mapping in endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 687-693.	1.7	6
352	The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 347-350.	2.5	6
353	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate™ Study. <i>Breast Care</i> , 2016, 11, 315-322.	1.4	6
354	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017, 22, 30.	2.2	6
355	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2114-2121.	5.1	6
356	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020, 12, 3021.	3.7	6
357	Update Breast Cancer 2020 Part 5 ‐ Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 469-480.	1.8	6
358	Update Breast Cancer 2021 Part 2 ‐ Advanced Stages, Long-Term Consequences and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 539-548.	1.8	6
359	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
360	Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7920.	2.6	6

#	ARTICLE	IF	CITATIONS
361	Reproducibility of mRNA-Based Testing of ESR1, PCR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment. <i>Cancers</i> , 2021, 13, 4718.	3.7	6
362	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e16128.	4.3	6
363	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	4.4	6
364	ABC6 Consensus: Assessment by a Group of German Experts. <i>Breast Care</i> , 2022, 17, 90-100.	1.4	6
365	Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 215-225.	1.8	6
366	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnancy and at birth in Franconia). <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 226-234.	1.8	6
367	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. <i>Cancer Research</i> , 2022, 82, PD13-06-PD13-06.	0.9	6
368	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011, 48, 698-702.	3.2	5
369	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
370	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019, 19, 611.	2.6	5
371	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. <i>Breast Care</i> , 2019, 14, 41-47.	1.4	5
372	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 289-294.	1.7	5
373	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. <i>Scientific Reports</i> , 2020, 10, 5171.	3.3	5
374	CYP3A7*1C allele: linking premenopausal oestrogen and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
375	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 145, 44-52.	2.8	5
376	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 637-653.	1.8	5
377	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	2.5	5
378	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5

#	ARTICLE	IF	CITATIONS
379	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. <i>Cancers</i> , 2021, 13, 5577.	3.7	5
380	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1854-1862.	7.0	5
381	MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 1721.	3.7	5
382	Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017, 189, 661-671.	1.3	4
383	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 147-152.	1.5	4
384	PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. <i>Cancers</i> , 2020, 12, 2742.	3.7	4
385	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	1.8	4
386	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. <i>Cancers</i> , 2021, 13, 2370.	3.7	4
387	Update Breast Cancer 2021 Part 3 â€œ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 654-665.	1.8	4
388	Update Breast Cancer 2021 Part 4 â€œ Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 206-214.	1.8	4
389	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.9	4
390	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	1.8	3
391	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
392	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€œ a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	1.8	3
393	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199.	2.4	3
394	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
395	Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 795580.	4.8	3
396	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	7.0	3

#	ARTICLE	IF	CITATIONS
397	Biomarkers in Women's Cancers, Gynecology, and Obstetrics. <i>BioMed Research International</i> , 2014, 2014, 1-2.	1.9	2
398	Does anxiety impact the neural processing of child faces in mothers of school-aged children? An ERP study using an emotional Go/NoGo task. <i>Social Neuroscience</i> , 2020, 15, 530-543.	1.3	2
399	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021, 16, 291-298.	1.4	2
400	Genetic variations in estrogen and progesterone pathway genes in preeclampsia patients and controls in Bavaria. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 897-904.	1.7	2
401	Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 519-519.	1.6	2
402	Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. <i>Reproductive BioMedicine Online</i> , 2021, 43, 788-798.	2.4	2
403	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	1.7	2
404	Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2014, 32, 578-578.	1.6	2
405	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
406	Genetic variants in the genes of the sex steroid hormone metabolism and depressive symptoms during and after pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 1763-1770.	1.7	2
407	Supportive Infusions in Integrative Breast and Gynecological Oncology – Report on Patients's Satisfaction and Self-reported Effects and Side Effects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1129-1137.	1.8	1
408	Response to Di Cosimo, Torri, and Porcu. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1234-1235.	6.3	1
409	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	2.6	1
410	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 588-600.	1.8	1
411	Genetic variants in the glucocorticoid pathway genes and birth weight. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 427-434.	1.7	1
412	Active Participation, Mind's Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199010.	2.0	1
413	Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. <i>Cancer Research</i> , 2021, 81, PS2-02-PS2-02.	0.9	1
414	OUP accepted manuscript. <i>Human Molecular Genetics</i> , 2022, , .	2.9	1

#	ARTICLE	IF	CITATIONS
415	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. European Journal of Cancer, 2022, 172, 13-21.	2.8	1
416	Response to –Screening depression during and after pregnancy using the EPDS–. Archives of Gynecology and Obstetrics, 2014, 290, 603-603.	1.7	0
417	Neoadjuvant Treatment of HER2-Positive Breast Cancer–”A Review. , 2019, , 95-106.		0
418	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	1.4	0
419	Risikoadaptierte Diagnostik und Therapie. , 2017, , 43-53.		0
420	Zukünftige Entwicklungen in der Bildgebung. , 2017, , 201-218.		0
421	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.. Journal of Clinical Oncology, 2020, 38, e12647-e12647.	1.6	0
422	Update Mammakarzinom 2021 Teil 1 –”Prävention und frühe Krankheitsstadien. Senologie - Zeitschrift für Mammadiagnostik Und -therapie, 2021, 18, 377-390.	0.0	0